Visterra, Pfizer deal

Visterra made its public debut by announcing its first pharma deal and presenting preclinical data for its lead compound. Visterra partnered with Pfizer to discover antibodies using the biotech's atomic interaction network analysis technology for undisclosed indications. Visterra will receive an upfront payment and research funding, and will be eligible for R&D milestones, plus royalties. Visterra's technology characterizes proteins as a 3D network of amino acids and covalent and non-covalent interactions. Visterra said the technology allows for the identification of unique epitopes on a target. Visterra declined to provide details on the partnership or financial terms, while Pfizer could not be reached for comment. ...